Evidence map›Paper›PMID 35874727›Full record

ArticleFrontiers in immunology2022

Transcriptome Analysis of Tumor-Infiltrating Lymphocytes Identifies NK Cell Gene Signatures Associated With Lymphocyte Infiltration and Survival in Soft Tissue Sarcomas.

Sean J Judge, Joshua D Bloomstein, Cyrus J Sholevar, Morgan A Darrow, Kevin M Stoffel, Logan V Vick, Cordelia Dunai, Sylvia M Cruz, Aryana M Razmara, Arta M Monjazeb and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Observational
  3. [Research progress in the role of STMN1 in tumor].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Intratumoral NKp46Frontiers in immunology · 2023
    Article
  9. The Density of CD8In vivo (Athens, Greece)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Sean J JudgeDivision of Surgical Oncology, Department of Surgery, University of California, Davis, Sacramento, CA, United States.
Joshua D BloomsteinDivision of Surgical Oncology, Department of Surgery, University of California, Davis, Sacramento, CA, United States.
Cyrus J SholevarDivision of Surgical Oncology, Department of Surgery, University of California, Davis, Sacramento, CA, United States.
Morgan A DarrowDepartment of Pathology and Laboratory Medicine, University of California, Davis, Sacramento, CA, United States.
Kevin M StoffelDepartment of Dermatology, University of California, Davis, Sacramento, CA, United States.
Logan V VickDepartment of Dermatology, University of California, Davis, Sacramento, CA, United States.
Cordelia DunaiDepartment of Dermatology, University of California, Davis, Sacramento, CA, United States.
Sylvia M CruzDivision of Surgical Oncology, Department of Surgery, University of California, Davis, Sacramento, CA, United States.
Aryana M RazmaraDivision of Surgical Oncology, Department of Surgery, University of California, Davis, Sacramento, CA, United States.
Arta M MonjazebDepartment of Radiation Oncology, University of California, Davis, Sacramento, CA, United States.
Robert B RebhunCenter for Companion Animal Health, Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, Davis, CA, United States.
William J MurphyDepartment of Dermatology, University of California, Davis, Sacramento, CA, United States.
Robert J CanterDivision of Surgical Oncology, Department of Surgery, University of California, Davis, Sacramento, CA, United States.
University of California, Davis · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
Gene Expression Analysis of Dog Natural Killer Cells Following Immunotherapy with Molecularly Targeted Radionuclide therapy or Inhaled IL-15U01CA224166 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CANTER, ROBERT J., REBHUN, ROBERT B · 2017 to 2021
$3.0M
Immunoregulatory and effector roles of natural killer cell subsetsR01HL140921 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MURPHY, WILLIAM JOSEPH · 2018 to 2021
$1.9M
UC Davis Comparative Oncology Training ProgramT32CA251007 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Robert J. Canter, Xinbin Chen · 2020 to 2026
$1.8M
UC Davis Shared Astrios Cell SorterS10OD018223 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SHACKLETT, BARBARA L. · 2015 to 2015
$555k
Shared LSRII Cytometer Equipment Application - UC Davis Stem Cell ProgramS10RR026825 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI NOLTA, JAN A. · 2010 to 2010
$500k
Acquisition of Covaris E220 and Sciclone G3 systems for high throughput sequencinS10OD010786 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI COMAI, LUCA · 2012 to 2012
$311k
Gene Expression Analysis of Dog Natural Killer Cells as Immunotherapy TargetR03CA252793 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CANTER, ROBERT J. · 2021 to 2022
$157k
NCI NIH HHS P30 CA093373NCI NIH HHS R03 CA252793NCI NIH HHS T32 CA251007NCI NIH HHS U01 CA224166NCRR NIH HHS S10 RR026825NHLBI NIH HHS R01 HL140921NIH HHS S10 OD010786NIH HHS S10 OD018223
6 · The paper itself

Abstract

Purpose: Clinical successes using current T-cell based immunotherapies have been limited in soft tissue sarcomas (STS), while pre-clinical studies have shown evidence of natural killer (NK) cell activity. Since tumor immune infiltration, especially tumor-infiltrating lymphocytes, is associated with improved survival in most solid tumors, we sought to evaluate the gene expression profile of tumor and blood NK and T cells, as well as tumor cells, with the goal of identifying potential novel immune targets in STS. Experimental Design: Using fluorescence-activated cell sorting, we isolated blood and tumor-infiltrating CD3 Results: Sorted intra-tumoral CD3 Conclusions: Unlike T cells, which demonstrate significant DGE consistent with upregulation of both activating and inhibiting receptors in tumor-infiltrating subsets, NK cells appear to have more stable gene expression between blood and tumor subsets, with alterations restricted primarily to metabolic pathways. Increased immune cell infiltration and improved survival were positively correlated with TLR4 expression and inversely correlated with STMN1 expression within tumors, suggesting possible novel therapeutic targets for immunotherapy in STS.

Indexed as

Killer Cells, NaturalLymphocytes, Tumor-InfiltratingSarcomaSoft Tissue NeoplasmsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansToll-Like Receptor 4TranscriptomeToll-Like Receptor 4immune infiltrateimmuno oncologyNK cellssoft tissue sarcoma (STS)T cellsTIL (tumor infiltrating lymphocytes)

Identifiers

PMID35874727
PMCPMC9300876
OpenAlexW4284706390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.